News
We are grateful to our existing and new investors for their support of Belite Bio’s recently announced $350M public offering. This important step further strengthens our organization as we prepare for potential commercialization, advance our pipeline, and continue building the infrastructure needed to support our long-term growth.
We remain focused on addressing the significant unmet need in Stargardt disease and geographic atrophy and advancing programs with the potential to meaningfully improve the lives of those affected by degenerative retinal diseases. We look forward to continued progress as we move our mission forward.
Posted Dec 3, 2025, 1:49 AM UTC
10